HCPLive Network
Latest Gastroenterology Headlines
By Desiree Cox, MBBS, PhD
A large multinational observational study of patients with hepatitis C reveals etiology does not play a major role in HCV survival rates and that early detection and access to treatment have a greater impact.
With the resignation of US Health and Human Services Secretary Kathleen Sebelius on Friday, the Affordable Care Act will get a fresh face. But turning around public perception of the controversial health care reform law in a politically charged mid-term election year poses an enormous challenge for the department's next leader, policy experts said.
By Desiree Cox, MBBS, PhD
Preliminary results from the M12-999 study show that treatment with ABT-450/ritonavir/ombitasvir plus dasabuvir and ribavirin is well tolerated and associated with high rates of sustained virologic response in adult liver transplant recipients with recurrent HCV genotype 1 infection.
Despite an overall improved mortality seen during the past 10 years, advancing age is associated with higher morbidity and mortality in colorectal cancer resection, according to a study published online April 9 in JAMA Surgery.
Individuals with chronic pancreatitis (CP) are at higher risk for cancer death and other comorbidities than those without CP, according to a study published in the April issue of Gastroenterology.
By Desiree Cox, MBBS, PhD
Results from the phase III ION-2 study show a 24-week regimen of sofosbuvir/ledipasvir does not produce significantly better cure rates than a 12-week regimen in treatment-experienced patients.
By Desiree Cox, MBBS, PhD
Results from the NEED study show combination treatment with peginterferon alpha-2a and either adefovir or entecavir does not increase HBeAg seroconversion rate compared to monotherapy alone in patients with hepatitis B.
By Desiree Cox, MBBS, PhD
Results from the SAPPHIRE-I trial show that Abbvie’s 3D therapy produced 96% sustained viral response rates at 12 weeks in treatment-naive patient with genotype 1 hepatitis C.
By Desiree Cox, MBBS, PhD
Data from the PEARL-I trial of patients with hepatitis C genotype 4 show high rates of sustained virologic response at 12 weeks associated with combination treatment with ABT-450 (a protease inhibitor boosted by ritonavir) and ombitasvir.
By Desiree Cox, MBBS, PhD
An 8-week course of treatment with a fixed dose combination of ledipasvir plus sofosbuvir produced sustained virologic response in more than 90 percent of treatment-naïve patients with genotype 1 hepatitis C.
Physician's Money Digest
Americans—regardless of age, income, and education—have proven to be pretty awful at handling their personal finances. Given the choice between saving and spending a sudden windfall, they’re more likely to spend the money.
Every time the top US tax rate increases by one percentage point, there is a more than 2% increase in US investors attempting to evade taxes by disguising themselves as foreign investors.
$AD300x250BB$